Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Alterity Therapeutics ( (AU:ATH) ) has issued an update.
Alterity Therapeutics has notified the market of the issue of 18 million unlisted options under its employee incentive scheme, each exercisable at $0.008 and expiring on 9 January 2031. The move expands the company’s pool of unquoted equity-based incentives, signalling continued reliance on options to motivate employees and align staff interests with long-term shareholder value, while incrementally increasing potential future dilution for existing investors.
The most recent analyst rating on (AU:ATH) stock is a Buy with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.
More about Alterity Therapeutics
Alterity Therapeutics Limited is a biotechnology company listed on the ASX under the code ATH. The company operates in the life sciences sector, focusing on the development of therapeutic treatments, and uses equity-based employee incentive schemes as part of its approach to attracting and retaining key staff.
Average Trading Volume: 14,979,325
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$87M
Find detailed analytics on ATH stock on TipRanks’ Stock Analysis page.